<DOC>
	<DOC>NCT01355172</DOC>
	<brief_summary>The purpose of this study is to evaluate the antibody response to each of the three influenza vaccine strains included in the seasonal flu vaccine(AdimFlu-S), as measured by hemagglutination inhibition (HAI) at 4 weeks after two doses of study vaccine, 4 weeks apart, in infants between 6 and 12 months of age.</brief_summary>
	<brief_title>Immunogenicity and Safety of AdimFlu-S, Formulation 2010-2011, in Infants Aged Between 6-12months Old</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<criteria>Boys or girls and aged &gt;= 6 months old to &lt;= 12 months old on the day of first vaccination; Subject's parent(s) or legal guardian(s) must be willing to comply with planned study procedures and be available for all study visits; Subject must be in good physical health on the basis of medical history, physical examination; Subject's parent(s) or legal guardian(s) must read and signed the studyspecific informed consent prior to initiation of any study procedure. Subjects had received influenza vaccine; History of hypersensitivity to eggs or egg protein or similar pharmacological effects to study medication; Personal or family history of Guillain Barre' Syndrome; An acute febrile illness within 1 week prior to vaccination; Current upper respiratory illness (URI), including the common cold or nasal congestion within 72 hours; Subjects with influenzalike illness as defined by the presence of fever (temperature &gt;= 38'C) and at least two of the following four symptoms: headache, muscle/joint aches and pains (e.g. myalgia/arthralgia), sore throat and cough;Treatment with an investigational drug or device, or participation in a clinical study, within 3 months before consent; Immunodeficiency, immunosuppressive or significant chronic illness not suitable for inactivated influenza vaccination; History of wheezing or bronchodilator use within 3 months prior to study vaccine; Receipt of live virus vaccine within 1 month prior to study vaccine or expected receipt vaccination before the last blood sampling for immunogenicity evaluation; Receipt of any inactivated vaccine within 2 weeks prior to study vaccination or expected receipt vaccination before the last blood sampling for immunogenicity evaluation; Receipt of any blood products, including immunoglobulin in the prior 3 months; Underlying condition in the investigators' opinion may interfere with evaluation of the vaccine.</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>1 Year</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immunogenicity</keyword>
</DOC>